Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study to Evaluate the Safety of Nanoxel M (Docetaxel-PM) Inj.

NCT04066335 is registered in ClinicalTrials.gov with Samyang Biopharmaceuticals Corporation as lead sponsor.

NCT NCT04066335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04066335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study to Evaluate the Safety of Nanoxel M (Docetaxel-PM) Inj.
Lead sponsor
Samyang Biopharmaceuticals Corporation
Phase
Observational
Overall status
Unknown status
Start date
September 18, 2019
Completion date
August 31, 2024
Enrollment
1,498 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, esophageal cancer, gastric cancer, head and neck cancer, non-small cell lung cancer, ovarian cancer, prostate cancer